Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NefXtend-SZ real-world follow-up in IgA nephropathy after 9 months of budesonide
ChiCTR2600128539Phase 4Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of budesonide in IgA nephropathy (IgAN), sponsored by Shenzhen Second People's Hospital. Primary endpoints: Urinalysis, Random urine total protein/creatinine ratio and 3 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
budesonide
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2600128539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128539.